Clinical Trial System 'Broken,' But Modernization Long Way Away – Woodcock
CDER Director says current system is stifles innovation, calls for integration of health care and trial process.
You may also be interested in...
Effort to replicate clinical trial results with real-world data could eventually allow for increased use in drug development.
Panel of experts stresses need to move toward innovative approaches for rare disease drug development such as Bayesian methods, but this would require a paradigm shift in US FDA's regulatory structure.
US FDA Commissioner says that with strong benefit shown, some risks can be discharged postmarket.